Donga ST and Aptis Present Ten Preclinical Findings on Anticancer Pipeline at AACR

Donga ST announced on April 24, 2026, that it presented ten preclinical research findings related to its next-generation anticancer pipeline at the American Association for Cancer Research (AACR 2026), alongside its subsidiary, ADC specialist Aptis. The presentations covered a range of topics, including PARP7 inhibitors, EGFR-targeted protein degraders, and bispecific antibody ADCs.

Donga ST and Aptis Unveil Next-Generation Anti-Cancer Pipeline at AACR. Donga ST

Donga ST explained that in the preclinical studies of its internally developed PARP7 inhibitor, 'SC5024', the company confirmed a 'dual anticancer mechanism' that simultaneously induces cancer cell suppression and immune activation, suggesting the potential for both monotherapy and combination therapy. In addition, Donga ST unveiled an anticancer treatment strategy that selectively eliminates EGFR-mutated proteins through the EGFR-targeted protein degraders 'SC3613' and 'SC3499', which are being co-developed with HK inno.N.

Donga ST and Aptis also introduced a therapeutic strategy based on their jointly developed bispecific antibody ADC platform. The Nectin-4×PD-L1, HER2×AXL, and Claudin18.2×HER2 bispecific antibody ADCs utilize Donga ST’s bispecific antibody platform along with Aptis’s linker conjugation technology. Target combinations were designed using omics and AI analysis of patient-derived cancer cells. According to the company, this approach suggests the possibility of overcoming both resistance and tumor heterogeneity issues simultaneously.

Aptis also presented preclinical results for a novel CD171 ADC compound aimed at treating solid tumors, as well as for the Claudin18.2 ADC, which has entered Phase 1 clinical trials.

O Yoonseok, Executive Vice President (CSO) of Donga ST, and Choi Hyungseok, President of Aptis, attended the conference to introduce the key pipelines and research strategies, and to discuss potential collaborations with global pharmaceutical companies.

Donga ST is strengthening decision-making based on selection and focus, as well as global-standard development strategies, under the leadership of Executive Vice President O Yoonseok, who has experience working at multinational pharmaceutical companies and the U.S. Food and Drug Administration (FDA). Meanwhile, Aptis is enhancing its drug development capabilities based on its third-generation linker technology, 'AbClick', and is focusing on building a pipeline centered on bispecific antibody ADCs.

A Donga ST representative stated, "Leveraging the synergy between Donga ST and Aptis, we will continue to expand our differentiated anticancer pipeline and achieve tangible results in the global market."

This content was produced with the assistance of AI translation services.